Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.
Also called NCT04030546
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 128 participants
- Sponsor
- Vilnius University
- Registry
-
NCT04030546
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Lithuania
- Registry status
- Unknown status
Technical summary
Registry record NCT04030546. Randomized; single masking; primary purpose treatment. Start 2019-06-01 (actual); primary completion 2020-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
- Condition
- Patients With Cancer
- Intervention (Drug)
- Ivabradine
- Lead sponsor
- Vilnius University
Record details
- Record id
cardio:ct-nct04030546- Content hash
e5f29e71eb8969ad1817f7088376b2a0920473fad98d099364a15dc715be11c9